What is she best known for?
The fields of study she is best known for:
- Cancer
- Gene
- Internal medicine
Cancer, Breast cancer, Internal medicine, Cancer research and Oncology are her primary areas of study.
Ana M. Gonzalez-Angulo combines subjects such as Pharmacology, Neovascularization and Pathology with her study of Cancer.
Her work carried out in the field of Breast cancer brings together such families of science as Immunohistochemistry and Carcinoma.
Her studies deal with areas such as Endocrinology and Surgery as well as Internal medicine.
Her research integrates issues of Mutation, PI3K/AKT/mTOR pathway, Signal transduction, Estrogen receptor and Kinase in her study of Cancer research.
Her Oncology research integrates issues from Neoadjuvant therapy, Chemotherapy, Retrospective cohort study, Gynecology and Proportional hazards model.
Her most cited work include:
- Comprehensive molecular portraits of human breast tumours (7253 citations)
- A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. (1296 citations)
- An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. (793 citations)
What are the main themes of her work throughout her whole career to date?
Her primary areas of study are Breast cancer, Internal medicine, Oncology, Cancer and Cancer research.
The Breast cancer study combines topics in areas such as Proportional hazards model, Surgery, Retrospective cohort study, Chemotherapy and Gynecology.
Her Internal medicine study frequently links to related topics such as Pathology.
Her biological study spans a wide range of topics, including Neoadjuvant therapy, Survival rate, Inflammatory breast cancer, Disease and Cohort.
She works mostly in the field of Cancer, limiting it down to topics relating to Bioinformatics and, in certain cases, Gene expression and Targeted therapy, as a part of the same area of interest.
Her Cancer research research focuses on PI3K/AKT/mTOR pathway and how it relates to Protein kinase B, In vivo and Mutation.
She most often published in these fields:
- Breast cancer (75.26%)
- Internal medicine (63.57%)
- Oncology (56.70%)
What were the highlights of her more recent work (between 2013-2021)?
- Breast cancer (75.26%)
- Internal medicine (63.57%)
- Oncology (56.70%)
In recent papers she was focusing on the following fields of study:
Her primary scientific interests are in Breast cancer, Internal medicine, Oncology, Cancer and Cancer research.
Her primary area of study in Breast cancer is in the field of Triple-negative breast cancer.
Her Internal medicine study deals with Surgery intersecting with Multivariate analysis, Confidence interval and Everolimus.
Her Oncology research includes elements of Trastuzumab, Chemotherapy, Phases of clinical research, Triple Negative Breast Neoplasms and Hazard ratio.
In the subject of general Cancer, her work in Neoadjuvant therapy is often linked to MK-2206, thereby combining diverse domains of study.
Her studies in Cancer research integrate themes in fields like PTEN, Mutation, Signal transduction, Estrogen receptor and In vivo.
Between 2013 and 2021, her most popular works were:
- Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor positive breast cancer (358 citations)
- Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline (234 citations)
- Perivascular M2 Macrophages Stimulate Tumor Relapse after Chemotherapy (196 citations)
In her most recent research, the most cited papers focused on:
- Cancer
- Gene
- Internal medicine
Ana M. Gonzalez-Angulo mainly investigates Breast cancer, Internal medicine, Oncology, Cancer and Chemotherapy.
Her Breast cancer research is multidisciplinary, incorporating elements of Cancer research, Gynecology, Proportional hazards model and PTEN.
She studied Internal medicine and Surgery that intersect with Multivariate analysis, Predictive value of tests and Recursive partitioning.
Her research in Oncology intersects with topics in Trastuzumab, Phases of clinical research, Clinical Oncology, Metastatic breast cancer and Prospective cohort study.
Her Cancer research incorporates themes from Biopsy, Pathology, Surgical oncology and Bioinformatics.
Her Triple-negative breast cancer research includes themes of Everolimus and Sirolimus.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
